COVID-KOSHA
Home
Help
(current)
Comment
!
Note: Language translations may be imperfect
A model anti-pandemic portal for scientists & public
High priority articles (R1, Most articles most likely to be relevant):
Second priority articles (R2, Moderate portion of articles likely to be relevant):
Other articles (R3, Lesser portion of articles likely to be relevant):
Molecular Interactions
Last updated: 2025 Mar 18
Total hit(s): 5927
S.No.
PMID
Ascending order
Descending order
Title
Ascending order
Descending order
Journal Name
Ascending order
Descending order
Publish Date
Ascending order
Descending order
Impact Factor
Ascending order
Descending order
Citations
Ascending order
Descending order
Auto summary
Ascending order
Descending order
1
39720838
Immunogenicity and safety of SARS-CoV-2 recombinant protein vaccine (CHO cell) LYB001 as a heterologous booster following two- or three-dose inactivated COVID-19 vaccine in adults aged >/=18 years: interim results of a randomized, active-controlled, double-blinded, phase 3 trial.
Expert Rev Vaccines
2025 Dec
4.37
1
2
39865693
Immunogenicity and safety of a COVID-19 DNA vaccine in healthy adults and elderly: A randomized, observer-blind, placebo-controlled phase 2 trial.
Hum Vaccin Immunother
2025 Dec
4.7
1
3
40077853
Characterization of the binding features between SARS-CoV-2 5'-proximal transcripts of genomic RNA and nucleocapsid proteins.
RNA Biol
2025 Dec
1
4
40045463
The characterization of technical design of a virus-like structure (VLS) nanodelivery system as vaccine candidate against SARS-CoV-2 variants.
Hum Vaccin Immunother
2025 Dec
4.7
1
5
40046771
Production and cryo-electron microscopy structure of an internally tagged SARS-CoV-2 spike ecto-domain construct.
J Struct Biol X
2025 Jun
1
6
39987705
Decoding SARS-CoV-2 variants: Mutations, viral stability, and breakthroughs in vaccines and therapies.
Biophys Chem
2025 May-Jun
1.75
1
7
39894142
Validation and clinical performance of a non-commercial ELISA for SARS-CoV-2 anti-RBD IgA antibodies.
Anal Biochem
2025 May
1
8
40043614
Structure and dynamics of Alpha B.1.1.7 SARS-CoV-2 S-protein in complex with Fab of neutralizing antibody REGN10987.
Biochem Biophys Res Commun
2025 Apr 1
2.73
1
9
40025551
Association of TNFRSF13B Gene Polymorphisms With SARS-CoV-2 Infection, Severity, and Humoral Immune Response in a Moroccan Population.
Int J Immunogenet
2025 Apr
1
10
40037139
Longitudinal humoral immunity against SARS-CoV-2 Spike following infection in individuals from Cameroon.
Virology
2025 Apr
2.819
1
11
40023068
Exploring the therapeutic potential of HAPC in COVID-19-induced acute lung injury.
Phytomedicine
2025 Apr
7.2
1
12
39999562
In silico tuning of binding selectivity for new SARS-CoV-2 main protease inhibitors.
Comput Methods Programs Biomed
2025 Apr
4.26
1
13
40057761
Impact of single nucleotide polymorphism of IL-27P28 rs153109 and IFITM3 rs12252 on susceptibility and severity of COVID-19 in Egyptian patients: a case control study.
Virol J
2025 Mar 8
2.45
1
14
39979118
Proteomics Reveals That Vitamin D Deficiency Leads to Immunoglobulin Abnormalities and Immune Dysregulation in Patients with Post-COVID-19 Condition.
J Proteome Res
2025 Mar 7
3.8
1
15
40056829
The comprehensive insights into the B-cells-mediated immune response against COVID-19 infection amid the ongoing evolution of SARS-CoV-2.
Biomed Pharmacother
2025 Mar 7
3.83
1
16
40042313
XBB.1.5 monovalent vaccine induces lasting cross-reactive responses to SARS-CoV-2 variants such as HV.1 and JN.1, as well as SARS-CoV-1, but elicits limited XBB.1.5 specific antibodies.
mBio
2025 Mar 5
6.5
1
17
40044778
Performance assessment of disposable carbon-based immunosensors for the detection of SARS-CoV-2 infections.
Sci Rep
2025 Mar 5
4.12
1
18
40049248
Developmental and reproductive toxicity (DART) study of a novel SARS-CoV-2 tetravalent recombinant protein vaccine (SCTV01E) in rats.
Reprod Toxicol
2025 Mar 4
1
19
40025489
Switching of OAS1 splicing isoforms overcomes SNP-derived vulnerability to SARS-CoV-2 infection.
BMC Biol
2025 Mar 3
1
20
40037239
Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Results of a randomized vaccine-controlled phase I ADAPTCOV trial in Brazil.
Vaccine
2025 Mar 3
3.31
1
21
40044551
Electrochemical pan-variant detection of SARS-CoV-2 through host cell receptor-mimicking molecular recognition.
Biosens Bioelectron
2025 Mar 3
9.52
1
22
39962897
Structural Changes at the Zinc Active Site of ACE2 on Binding the SARS-CoV-2 Spike Protein Receptor Binding Domain.
Inorg Chem
2025 Mar 3
1
23
40060909
Mutational pressure promotes release of public CD8(+) T cell epitopes by proteasome from SARS-CoV-2 RBD of Omicron and its current lineages.
iScience
2025 Mar 21
4.447
1
24
39970838
Novel nanobody drug conjugate as a prophylactic or therapeutic against SARS-CoV-2 infection in mice.
Biochem Biophys Res Commun
2025 Mar 19
2.73
1
25
40096751
Efficient one-step immobilization of DNA probes on 1DZnO nanoplatforms targeting a low-mutation region of SARS-CoV-2.
Biofabrication
2025 Mar 17
1